In this expert perspective from Hawaiian Eye 2025, W. Lloyd Clark, MD, discusses the use of aflibercept 8 mg in the treatment of retinal vein occlusion.

In this expert perspective from Hawaiian Eye 2025, Ashkan M. Abbey, MD, discusses an advancement in retinal vein occlusion treatment from 2024 and highlights a treatment in the pipeline for 2025.

The FDA and European Medicines Agency (EMA) mandate high similarity between biosimilars and reference products, but their ...

Last year marked an all-time record of 18 Food and Drug Administration (FDA) biosimilar approvals, bringing the total number ...

FYB203, a biosimilar to aflibercept, received UK MHRA approval for multiple retinal conditions and will be marketed as ...

Retinal Biologics MarketThe Retinal Biologics Market generated USD 19.96 billion in revenue in 2021 and is projected to grow ...